ClinicalTrials.gg
CompletedNCT07115355RUCS-PPHUpdated Aug 11, 2025

Evaluating the Safety and Efficacy of RUCS in PPH

An observational study in Postpartum Hemorrhage, sponsored by Havva Betül Bacak. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by Havva Betül Bacak · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
11
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Postpartum Hemorrhage with a site in Turkey — 4 open to participants now, 5 under way, none of them phase 3. Postpartum Hemorrhage · Turkey.

Enrollment
10th of 10
11 · median 88
Started
2020
with 1 other
Observational
10 of 45
none open now
Registered
34th of 45
by date

Among the 45 studies in Postpartum Hemorrhage with a site in Turkey, this one is the 10th largest by enrollment of the 10 observational ones that give a count, is one of 2 that started in 2020, is one of 10 observational ones, and was the 34th registered.

Postpartum Hemorrhage

471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.

Browse Postpartum Hemorrhage studies →

Open to participants now

4 of the 45 studies in Postpartum Hemorrhage with a site in Turkey are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Postpartum Hemorrhage with a site in Turkey, or all of them as a file.
02

Study summary

This retrospective observational study aims to evaluate the efficacy and safety of Removable Uterine Compression Sutures (RUCS) in the surgical management of postpartum hemorrhage (PPH). Eleven patients who developed PPH and underwent RUCS between January 2020 and November 2024 at Gaziosmanpaşa Training and Research Hospital were included. The primary outcomes assessed were hemorrhage control and procedure-related complications. Data were collected from patient records and analyzed descriptively.

Read the detailed description

Postpartum hemorrhage (PPH) remains one of the leading causes of maternal morbidity and mortality worldwide. When medical management is insufficient, surgical interventions become necessary. Removable Uterine Compression Sutures (RUCS) have been developed as a uterus-sparing surgical technique that may offer effective hemostasis with a potentially lower risk of complications such as intrauterine synechiae, when compared to traditional permanent suture methods.

This single-center retrospective observational case series evaluated 11 patients who experienced PPH and were treated with RUCS at the Obstetrics and Gynecology Clinic of Gaziosmanpaşa Training and Research Hospital between January 2020 and November 2024. Patients were included if they had complete medical records and underwent RUCS after delivery. Cases involving other surgical techniques or missing data were excluded.

Clinical data were extracted from hospital archives and electronic medical systems. All data were anonymized prior to analysis. Descriptive statistics were used, including means and standard deviations for continuous variables and frequencies for categorical variables.

The study aimed to assess both the efficacy of RUCS in controlling bleeding and its safety by monitoring postoperative complications such as intrauterine synechiae and uterine necrosis. Initial findings indicate 100% success in hemostasis with no observed major complications, suggesting that RUCS may be a safe and effective option in selected cases of postpartum hemorrhage.

03

Conditions studied

  • Postpartum Hemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of women aged 18-45 who developed postpartum hemorrhage following delivery and were treated with Removable Uterine Compression Sutures (RUCS) at Gaziosmanpaşa Training and Research Hospital between January 2020 and November 2024. Only patients with complete and accessible medical records were included in this retrospective case series.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female patients aged 18 to 45 years Diagnosed with postpartum hemorrhage (PPH) following delivery Treated with Removable Uterine Compression Suture (RUCS) Delivery and treatment performed at Gaziosmanpaşa Training and Research Hospital RUCS performed between January 2020 and November 2024 Complete and accessible medical records

Exclusion criteria

Exclusion Criteria:

Incomplete or missing medical records Use of alternative surgical techniques other than RUCS Patients outside the age range of 18-45 Cases not treated at Gaziosmanpaşa Training and Research Hospital Postpartum hemorrhage not managed with RUCS

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
11 participants (actual)
Patient registry
No

Groups and cohorts

  • RUCS Group

    This group includes women aged 18-45 who experienced postpartum hemorrhage and were treated with Removable Uterine Compression Sutures (RUCS) at Gaziosmanpaşa Training and Research Hospital between January 2020 and November 2024. All patients had complete medical records and underwent retrospective data analysis.

    Procedure: Removable Uterine Compression Suture (RUCS)

Interventions

  • ProcedureRemovable Uterine Compression Suture (RUCS)

    Removable Uterine Compression Suture (RUCS) is a uterus-preserving surgical technique used to control postpartum hemorrhage (PPH) when medical management fails. The suture is placed in a way that allows for its removal after hemostasis is achieved, potentially reducing the risk of complications such as intrauterine synechiae. In this study, RUCS was applied to 11 patients following delivery-related hemorrhage.

06

What researchers measure

Primary outcomes

  1. Hemostasis success rate following RUCS application

    Successful control of postpartum bleeding without the need for additional surgical intervention, blood transfusion exceeding 4 units, or hysterectomy.

    Time frame: Within the first 24 hours post-procedure

07

Study locations

1 site
  • Gaziosmanpaşa Training and Research Hospital
    Istanbul, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Nov 2024, 58 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 11, 2025
StartActual
Jan 1, 2020
Primary completionActual
Nov 30, 2024
CompletionActual
Jun 1, 2025
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07115355
Lead sponsor
Havva Betül Bacak
Responsible party
Havva Betül Bacak (Specialist in Obstetrics and Gynecology, Gaziosmanpasa Research and Education Hospital) — Sponsor-investigator
First posted
Aug 11, 2025
Start date
Jan 1, 2020
Primary completion
Nov 30, 2024
Completion
Jun 1, 2025
Last update
Aug 11, 2025

Study contacts

fatih irice, md
study chair · University of Health Sciences, Gaziosmanpaşa Training and Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion